Spots Global Cancer Trial Database for A Phase I Study of Famitinib Malate in Patients With Solid Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of Famitinib Malate in Patients With Solid Tumor
Official Title: A Phase I Study of Famitinib Malate in Patients With Solid Tumor
Study ID: NCT01762280
Conditions
Interventions
Study Description
Brief Summary: Famitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Famitinib in patients with solid tumor
Detailed Description: 1. To evaluate the safety and tolerability of Famitinib, and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). 2. To determine the pharmacokinetic profile of Famitinib and its metabolites . 3. To assess preliminary antitumor activity . 4. To determine preliminary dose and regimen for phase II study .
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Cancer Institute and Hospital Chinese Academy of Medical Sciences, Beijing, , China
Contact Details
Name: Jinwan Wang, M.D
Affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Role: PRINCIPAL_INVESTIGATOR
Name: Dafang Zhong, Ph.D
Affiliation: Chinese Academy of Science Shanghai Institution of Materia Medica
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
